Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab)
Recombinant Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| FC, E, FTA |
---|---|
Primary Accession | P32970 |
Reactivity | Cynomolgus, Human, Mouse |
Clonality | Monoclonal |
Isotype | IgG1 |
Calculated MW | 144.36 KDa |
Target/Specificity | TNFSF7 / CD27L / CD70 |
---|---|
Endotoxin | < 0.001EU/ µg,determined by LAL method. |
Conjugation | Unconjugated |
Expression system | CHO Cell |
Format | Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column. |
Storage | -80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions;Avoid repeated freeze-thaw cycles. |
Name | CD70 |
---|---|
Synonyms | CD27L, CD27LG, TNFSF7 |
Function | Cytokine which is the ligand for CD27. The CD70-CD27 pathway plays an important role in the generation and maintenance of T cell immunity, in particular during antiviral responses. Upon CD27 binding, induces the proliferation of costimulated T-cells and enhances the generation of cytolytic T-cells. |
Cellular Location | Membrane; Single- pass type II membrane protein |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.